Could cause temporary or reversible harm; serious harm is unlikely.
Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)
| Brand name | KETOROLAC TROMETHAMINE |
| Generic name | KETOROLAC TROMETHAMINE |
| Active ingredient(s) | KETOROLAC TROMETHAMINE |
| Distributed by / for | Hikma Pharmaceuticals USA Inc. |
| NDC | 0641-6043-01 |
| Full product label | Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (NDC 0641-6043-25), For IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA. |
| Recalling firm | Hikma Pharmaceuticals USA Inc. |
| Distribution | Nationwide within the United States |
| Quantity | 25,817 shelf packs/25 vials per pack |
| Recall initiated | 2019-12-17 |
| Report date | 2020-01-22 |
| Recall completed | 2021-06-09 |
| Recall number | D-0658-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Cherry Hill NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗